Dec 08, 2021 7:30am EST Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Nov 10, 2021 9:00am EST Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
Nov 01, 2021 9:00am EDT Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
Sep 16, 2021 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment
Sep 15, 2021 8:30am EDT Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System
Sep 09, 2021 7:05am EDT Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 08, 2021 7:05am EDT Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
